Market Signal Briefing

Key Takeaways DUK posted Q4 EPS of $1.50, missing estimates and falling 9.6% year over year despite revenue growth.Duke Energy's Q4 revenues rose 7.9% to $7.94B, beating estimates, while full-year sales reached $32.24B.Higher fuel, depreciation and interest costs pressured earnings, even as customers and sales volumes grew. Duke Energy Corporation's (DUK - Free Report) fourth-quarter 2025 earnings of $1.50 per share lagged the Zacks Consensus Estimate of $1.51 by 0.6%. The bottom line also declined 9.6% from $1.66 reported in the year-ago quarter.

For 2025, CMS reported adjusted earnings of $6.31 per share, higher than the prior-year figure of $5.90.

DUK’s Total RevenuesTotal operating revenues were $7.94 billion, which beat the Zacks Consensus Estimate of $7.66 billion by 3.9%. The top line also increased 7.9% from $7.36 billion in the year-ago period.

The company reported revenues of $32.24 billion in 2025, higher than $30.36 billion in 2024.

Highlights of DUK’s Earnings ReleaseTotal operating expenses amounted to $5.83 billion in the reported quarter, up 11% year over year. The increase was primarily driven by higher expenses for the cost of natural gas, operation, maintenance and other, depreciation and amortization, as well as property and other taxes.

The operating income totaled $2.119 billion compared with $2.112 billion in the year-ago quarter.

Interest expenses rose to $946 million from $871 million in the fourth quarter of 2024.

The average number of customers in its Electric Utilities increased 1.5% year over year.

Total electric sales volume for the reported quarter went up 2.3% year over year to 61,726 gigawatt-hours.

DUK’s Segmental HighlightsElectric Utilities & Infrastructure: This segment’s adjusted earnings for the fourth quarter totaled $1.21 billion, down from $1.24 billion in the fourth quarter of 2024. The decline was mainly due to higher O&M and depreciation on a growing asset base and interest expense, partially offset by the recovery of infrastructure investments.

Gas Utilities & Infrastructure: Adjusted earnings from this segment amounted to $230 million compared with $231 million in the fourth quarter of 2024.

Other: The segment includes corporate interest expenses not allocated to other business units, resulting from Duke Energy’s captive insurance company and other investments. This segment incurred a loss of $272 million compared with a loss of $186 million in the fourth quarter of 2024.

Financial Condition of DUKAs of Dec. 31, 2025, Duke Energy had cash & cash equivalents of $245 million compared with $314 million as of Dec. 31, 2024.

As of Dec. 31, 2025, the long-term debt was $80.11 billion compared with $76.34 billion as of Dec. 31, 2024.

The company generated net cash from operating activities of $12.330 billion in 2025 compared with $12.328 billion last year.

2026 Guidance by DUKDuke Energy expects to generate 2026 adjusted EPS in the range of $6.55-$6.80. The Zacks Consensus Estimate for 2025 earnings is pegged at $6.70, which is higher than the midpoint of the company’s projected range.

DUK extends its long-term EPS growth of 5-7% through 2030.

DUK’s Zacks RankUpcoming Utility ReleasesEdison International (EIX - Free Report) is scheduled to report fourth-quarter results on Feb. 18, after market close. The Zacks Consensus Estimate for earnings is pegged at $1.47 per share, which suggests a year-over-year increase of 40%.

EIX’s long-term (three to five years) earnings growth rate is 10.93%. The Zacks Consensus Estimate for fourth-quarter sales is pinned at $4.38 billion, which implies a year-over-year improvement of 9.9%.

Alliant Energy (LNT - Free Report) is slated to report fourth-quarter results on Feb. 19, after market close. The Zacks Consensus Estimate for earnings is pegged at 58 cents per share, which implies a year-over-year decrease of 17.1%.

LNT’s long-term earnings growth rate is 7.15%. The Zacks Consensus Estimate for fourth-quarter sales is pinned at $937.84 million, which implies a year-over-year decline of 3.9%.

AES Corporation (AES - Free Report) is slated to report fourth-quarter results on Feb. 26, after market close. The Zacks Consensus Estimate for earnings is pegged at 62 cents per share, which implies a year-over-year increase of 14.8%.

AES’ long-term earnings growth rate is 11.17%. The Zacks Consensus Estimate for fourth-quarter sales is pinned at $3.49 billion, which implies year-over-year growth of 17.8%.

Key Takeaways ORCL jumped nearly 10% on Feb. 9 after D.A. Davidson upgraded the stock to Buy with a $180 price target.The upgrade cites a correction after a 25% drop and stabilizing sentiment around ORCL's AI exposure. ETFs like IGV offer diversified exposure to ORCL while reducing single-stock risk. Following a week of general tech selloffs that caused a sector-wide loss of nearly $1 trillion, Oracle Corporation (ORCL - Free Report) emerged as a bright spot in the stock market. Its shares jumped nearly 10% on Feb. 9 after a D.A. Davidson analyst upgraded the stock to ‘Buy,’ reigniting investor interest in the software giant.

For those looking to capitalize on this momentum without the concentrated risk of a single stock, gaining exposure through Exchange-Traded Funds (ETFs) offers a diversified way to benefit from Oracle’s upward trajectory.

Before delving into the names and specifics of these ETFs, let us first examine what prompted the D.A. Davidson analyst to upgrade

ORCL and whether the stock truly offers upside potential. We also explain why ETF exposure, rather than direct stock ownership, is recommended. To support this view, we present the following analysis.

What Led to the Upgrade?Analyst Gil Luria of D.A. Davidson upgraded Oracle, maintaining a $180 price target, based on two core convictions:

1.    Market Overreaction Correcting: Luria believes the recent plunge in Oracle’s share price — down roughly 25% over eight sessions — was an overcorrection. He stated that the sentiment toward Oracle’s AI exposure was beginning to stabilize.

2.    OpenAI's Financial Strength as a Key Catalyst: Another key driver of the upgrade is the improved outlook for OpenAI, a major Oracle cloud customer. In this context, Luria estimated that OpenAI already has around $40 billion in cash and could raise another $100 billion in the near term (as cited in Trading View). This funding is critical to financing the data centers Oracle is building for the AI leader. Luria believes the fundraising will serve as a catalyst for the stock’s outperformance.

Can Oracle Sustain the Share Price Hike?As Oracle’s forward-looking strategy remains deeply rooted in the generative AI revolution, some analysts, including Luria, express a bullish view on the software giant’s future trajectory, largely based on excerpts from its most recent earnings call transcript:

•    Explosive Cloud Infrastructure Growth: Oracle Cloud Infrastructure (“OCI”) revenues grew 66% year over year in the fiscal second quarter, with GPU-related revenues skyrocketing 177%. The company reported handing over nearly 400 megawatts of data center capacity and delivering GPU capacity that is 50% higher than the prior quarter.

•    Massive and Diversified Backlog: Another factor supporting a bullish view on the stock is Oracle’s sizable remaining performance obligations (RPO) of $523.3 billion, which rose 433% year over year. This backlog, driven by high-capacity contracts with giants like Meta and NVIDIA, provides a highly visible and stable revenue runway that sets Oracle apart from its peers. 

Oracle’s story is complex, involving a planned $50 billion capital raise and significant debt, which could introduce volatility and limit the appeal of a single-stock investment, particularly at the current premium valuation. ORCL trades at a trailing 12-month earnings multiple of 27.57, slightly above the industry average of 27.4. Its long-term debt-to-equity ratio is 328.28, far higher than the sector average of 25.35.

On the same day, Luria upgraded Oracle, Melius Research downgraded the stock to Hold from Buy, citing its significant debt load and questioning its valuation given the expectation of no free cash flow until the 2030s (as cited in Yahoo Finance). This implies that not all analysts maintain a bullish stance on ORCL.

ETFs to Bet OnIn light of the discussion above, investors may look to the following ETFs with significant ORCL exposure to participate in Oracle’s AI opportunity while reducing company-specific financial and execution risks through diversification.

iShares Expanded Tech-Software Sector ETF (IGV - Free Report)

This fund, with net assets worth $7.37 billion, provides exposure to 114 software companies in the technology and communication services sectors. Of these, Oracle holds the fourth spot, with a 7.30% share of the fund.

This fund charges 39 basis points (bps) as fees. It traded at a good volume of 28.98 million shares in the last trading session. 

Pacer Data and Digital Revolution ETF (TRFK - Free Report)

This fund, with net assets worth $453 million, provides exposure to 87 data and digital revolution companies. Of these, Oracle holds the fifth spot, with a 7.20% share of the fund.

This fund charges 49 bps as fees. It traded at a good volume of 0.09 million shares in the last trading session. 

Janus Henderson Transformational Growth ETF (JXX - Free Report)

This fund, with net assets worth $33.6 million, provides exposure to 24 companies benefiting from durable trends transforming society, including AI, deglobalization, health care innovation, digitization and migration to the cloud. Of these, Oracle holds the fourth spot, with a 7.50% share of the fund.

This fund charges 57 bps as fees. It traded at a good volume of 0.02 million shares in the last trading session.

First Trust NASDAQ Technology Dividend ETF (TDIV - Free Report)

This fund, with net assets worth $3.80 billion, provides exposure to 93 technology and telecommunications companies that pay a regular or common dividend. Of these, Oracle holds the fifth spot, with a 5.04% share of the fund.

This fund charges 50 bps as fees. It traded at a good volume of 0.11 million shares in the last trading session. 

For investors seeking momentum, the THOR Equal Weight Low Volatility ETF (THLV - Free Report) is probably on the radar now. The fund just hit a 52-week high and is up 28.4% from its 52-week low price of $25.26 per share.  

But are there more gains in store for this ETF? Let’s take a quick look at the fund and its near-term outlook to get a better sense of where it might head.

THLV in FocusThe fund provides exposure to U.S. large-cap equities while attempting to lower volatility by avoiding sectors that are currently in a down-trending cycle. The fund charges 64 basis points (bps) in annual fees (See: all Style-Box Large-Cap Blend ETFs here).

What Led to the Rise?THLV has recently benefited from equal-weight allocations to materials and health care, sectors that outperform during periods of market volatility. Its systematic avoidance of risk-off sectors allows it to capture market upside while maintaining a low-volatility posture, pushing the fund toward a 52-week high.

More Gains Ahead?THLV may continue its strong performance in the near term, with a positive weighted alpha of 20.41 (as per Barchart.com), which suggests a further rally.

CVS Health Corp (NYSE:CVS) on Tuesday reported stronger-than-expected fourth-quarter revenue and adjusted earnings, driven by growth across its pharmacy, health services, and insurance businesses.

The US pharmacy chain and health insurer said fourth-quarter revenue rose 8.2% to $105.7 billion, topping analysts’ expectations of $103.6 billion.

Adjusted earnings per share (EPS) came in at $1.09, above the $1.00 forecast. GAAP net income for the quarter was $2.923 billion, with operating income of $2.112 billion.

Full-year 2025 revenue climbed 7.8% to a record $402.1 billion. Adjusted EPS for the year was $6.75, while GAAP diluted EPS was $1.39. The company generated $10.6 billion in cash flow from operations for the year.

Operationally, CVS said its pharmacy segment completed the transition to cost-based reimbursement across commercial, Medicare, and Medicaid businesses. Health insurer Aetna approved more than 95% of all eligible prior authorizations within 24 hours, with many processed instantaneously. CVS Caremark also reported strong customer retention and wins heading into 2026.

Looking ahead, CVS confirmed its 2026 full-year guidance for adjusted EPS at $7 to $7.20, slightly above analysts’ estimate of $7.17. GAAP EPS guidance is set at $5.94 to $6.14. The company updated its cash flow from operations guidance to at least $9 billion, down from the previous $10 billion.

“Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses,” CVS CEO David Joyner said. “From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.”

Shares rose 2.6% in early trading.

February 10, 2026 09:00 ET  | Source: Carlsmed

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo® Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado.

“This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to help surgeons plan with greater precision, improve patient outcomes, and reduce costly revisions. The addition of the aprevo® Bi-lateral Posterior Lumbar Interbody Fusion procedure to our personalized surgery procedure portfolio further demonstrates the power and versatility of our personalized, AI-enabled approach to spine surgery,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “We look forward to our full commercial launch this year to provide this personalized procedural option to patients, surgeons, and hospital systems on a larger scale.”

“Carlsmed’s aprevo® technology is integral to my pre-operative, intra-operative, and post-operative workflow, and extending its use across additional lumbar fusion approaches allows me to more precisely tailor treatment to each patient,” said Dr. Kleck. “Being able to personalize procedures based on each patient’s anatomy and pathology gives me greater confidence in achieving alignment goals. Adding a Bi-lateral posterior system to the list of procedures addressable with aprevo® will enable me to utilize this technology across a broader range of patients.”

Carlsmed’s Bi-lateral Posterior Fusion System integrates seamlessly with the Company’s broader aprevo® platform technology, which combines proprietary AI-enabled software and clinical intelligence to deliver personalized surgical strategies and preoperative planning across a range of spinal pathologies. The Company expects to commercially launch the system later this year.

About Carlsmed 
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about the timing of the commercial launch of the Company’s Bi-Lateral Posterior Fusion System, the potential of the Company’s products, the ability of the Company’s products to improve patient outcomes and reduce revision surgeries, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations 
Caroline Corner, PhD
[email protected] 

Media 
LeAnn Burton 
Senior Director Brand Marketing 
[email protected] 

The new partnership combines Weight Watchers’ scientifically-backed medical and behavioral expertise with PVOLVE’s clinically-studied method to support members at every age and stage of life February 10, 2026 09:00 ET  | Source: WW International Inc.

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced a strategic partnership with PVOLVE, the clinically validated workout method, designed to support longevity through strength, mobility, and stability training.

As weight health enters a new era driven by GLP-1 medications and growing awareness of the role lean muscle plays in metabolism, Weight Watchers continues to innovate its science-backed approach to deliver even stronger outcomes for members. Building and preserving muscle plays an important role in long-term health, especially for women in midlife and members using GLP-1 medications.

To meet these evolving needs, Weight Watchers is further expanding its integrated approach by deepening its strength-forward movement offerings through PVOLVE’s clinically validated method to support members throughout their weight health journey and promote overall longevity.

Starting today, Weight Watchers members will gain access to exclusive PVOLVE classes suitable for all fitness levels and life stages through the WeightWatchers Core, Core+, Med+, GLP-1 Success and Menopause programs. Members will also be able to upgrade to PVOLVE’s full on-demand library through Weight Watchers and purchase a curated starter kit featuring PVOLVE’s best-selling unique resistance equipment.

For members using GLP-1 medications, strength training plays a critical role in supporting lean muscle and long-term success. The Weight Watchers Med+ Program, which includes their GLP-1 Success Program combines board-certified clinicians, behavioral science, personalized nutrition, strength-building plans, and expert coaching and community support to help manage side effects and deliver better outcomes than medication alone.

Data shows the positive impact of this integrated approach. At one month, regularly engaged Weight Watchers Med+ members lost 61.3% more body weight than those who took medicine alone; and at twelve months, 29.1% more.

Women lose 3-5% of muscle mass per decade, starting at age 30, but PVOLVE’s workouts have been shown to help partially offset this decline. In a 12-week PVOLVE program, participants experienced significant increases in lean muscle mass and improved lower body strength by 19%.

By pairing Weight Watchers’ holistic approach to nutrition, behavior change support, and medical care with PVOLVE’s fitness method, members receive a more personalized and comprehensive approach to weight health.

"As the definition of weight health evolves, so does our approach,” said Julie Rice, Chief Experience Officer of Weight Watchers. “This partnership with PVOLVE builds on our foundation by bringing more strength-forward movement into our ecosystem alongside nutrition, behavior change, coaching, and medical care - so our members can achieve more sustainable, long-term results."

“Movement should empower you, not exhaust you,” said Rachel Katzman, Founder of PVOLVE. “PVOLVE was created to help people feel strong, capable, and confident in their bodies through every stage of life, and we saw a natural partnership with Weight Watchers in that shared vision. For more than six decades, they’ve supported millions of people with a science-backed, comprehensive approach to health, and together we’re bringing movement, nutrition, medical care and coaching together in a way that truly supports real, lasting change and longevity.”

What Members Receive Through Weight Watchers + PVOLVE Partnership:
As part of the collaboration, all Weight Watchers members will gain access to exclusive benefits from PVOLVE, including:

Weight Watchers + PVOLVE Streaming Membership: Immediate access to select custom PVOLVE workouts through the Weight Watchers app – designed for all fitness levels and life stages, with specialized series for women in perimenopause and menopause, and a dedicated GLP-1 strength series.Expanded PVOLVE streaming experience: The opportunity to unlock the full PVOLVE library of 1,700+ on-demand classes through the Weight Watchers app at a special reduced member rate.Weight Watchers + PVOLVE Starter Kit: A curated kit featuring PVOLVE’s best-selling essentials, which include – Gliders, Floor Gloves, Heavy Ankle Band, P.ball, and P.band, also at a reduced member rate. As weight health solutions become increasingly fragmented, Weight Watchers is setting the industry standard by delivering a fully integrated experience that unites medical care, nutrition, behavior change, and movement in one connected platform. The partnership with PVOLVE builds on this foundation to further recognize strength, mobility, and muscle preservation as essential contributing pillars of lasting weight health.

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

ABOUT PVOLVE
PVOLVE is the first clinically-proven movement longevity company- built on a method that uniquely combines the three pillars of longevity training: strength, mobility, and stability. Using patented resistance equipment and functional movement patterns, PVOLVE sculpts and tones the body while helping members move better, longer. Founded by Rachel Katzman in 2017, the PVOLVE Method is backed by a Clinical Advisory Board of expert physicians and highly credentialed trainers with expertise in human physiology and biomechanics. In June 2023, world-renowned actress Jennifer Aniston officially partnered with PVOLVE after experiencing transformative results, calling the method “a game changer” for how she felt and looked. PVOLVE has a hybrid fitness model, offering more than 1,700 on-demand workouts, a two-way live virtual studio, and targeted series across web and mobile apps. The brand has over 30 studio locations open across North America, with more than 50 additional studios in development. Learn more at pvolve.com and pvolvefranchise.com.

For media inquiries, please contact:
Lizzy Levitan 
[email protected]

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

February 10, 2026 09:00 ET  | Source: MKS Inc.

ANDOVER, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.25 per share, an increase of 14% from its Q4 2025 dividend, payable on March 6, 2026, to shareholders of record as of February 23, 2026.

Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors.

About MKS Inc.
MKS Inc. (NASDAQ: MKSI) enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems, process control solutions and specialty chemicals technology that improve process performance, optimize productivity and enable unique innovations for many of the world’s leading technology and industrial companies. Our solutions are critical to addressing the challenges of miniaturization and complexity in advanced device manufacturing by enabling increased power, speed, feature enhancement, and optimized connectivity. Our solutions are also critical to addressing ever-increasing performance requirements across a wide array of specialty industrial applications. Additional information can be found at www.mks.com.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding MKS’ dividend program and any future dividend payment obligations. Any statements that are not statements of historical fact should be considered to be forward-looking statements. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Among the important factors that could cause actual events to differ materially from those in the forward-looking statements are cash available for distribution, the then current and expected needs and availability of cash to pay MKS’ obligations, and the other factors described in MKS’ Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Quarterly Reports on Form 10-Q, as filed with the U.S. Securities and Exchange Commission. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

MKS Investor Relations Contact:
Paretosh Misra
Vice President, Investor Relations
Telephone: +1 (978) 284-4705
Email: [email protected]

Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary fibrosis , /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD); (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced a potential expanded therapeutic application for Thykamine™, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of pulmonary fibrosis.

The study investigated the effects of Thykamine™ in bleomycin-induced pulmonary fibrosis (IPF) mouse model, a widely used preclinical tool for studying idiopathic pulmonary fibrosis (IPF) pathophysiology and testing antifibrotic therapies. Pulmonary fibrosis was induced in mice using intranasal bleomycin, a gold-standard and clinically relevant model that closely mirrors key pathological features of human idiopathic pulmonary fibrosis.

Thykamine™ was administered orally at doses of 0.05, 0.1, 0.25, 0.5, and 1 mg/kg, and benchmarked against pirfenidone dosed at 220 mg/kg. Over a 21-day period, animals were monitored for body weight and survival, followed by comprehensive lung assessment. Fibrotic burden was evaluated through lung weight, collagen content, fibrosis-related gene expression, and histopathological scoring.     

In this bleomycin-induced pulmonary fibrosis model, Thykamine™ demonstrated statistically significant antifibrotic activity, while pirfenidone did not reach statistical significance in physiological endpoints. Treatment with Thykamine™ at 0.5 mg/kg significantly reduced lung wet weight and lung tissue index compared with the bleomycin/vehicle group.

Bleomycin exposure led to marked increases in fibrosis (Ashcroft score) and inflammation compared with sham controls. Thykamine™ treatment significantly reversed these pathological changes, reducing both fibrosis and inflammation scores and indicating meaningful improvement in lung morphology.

Consistent with its effects on lung pathology, Thykamine™ at 0.5 mg/kg produced a statistically significant downregulation of key fibrosis- and inflammation-associated genes, including Fn1 (fibronectin), Col1a1, Col3a1, Col6a1, and Col6a3 (collagen isoforms involved in extracellular matrix deposition), Birc5, and the chemokines Ccl2 and Cxcl2 (inflammatory cell recruitment). In parallel, Thykamine™ significantly increased Mmp9, a matrix metalloproteinase associated with extracellular matrix turnover, while reducing Mmp13, a collagenase often linked to progressive tissue injury and inflammation. Together, this gene expression profile is consistent with controlled matrix remodeling and attenuation of fibrotic progression. 

This well-validated model delivers a strong, dose-responsive demonstration of antifibrotic efficacy across multiple translational endpoints, clearly positioning Thykamine™ as a differentiated, next-generation therapeutic candidate in pulmonary fibrosis. The Company plans to present data in an upcoming scientific publication.

"These results represent a major inflection point for Thykamine™," said Dr. Andre P. Boulet, PhD, Chief Executive Officer. "The pulmonary fibrosis data not only confirm and extend the antifibrotic effects we previously observed in mouse MASH model, but also significantly broaden Thykamine™'s mechanism of action. By combining potent anti-inflammatory and anti-fibrotic activity at low doses, Thykamine™ demonstrates clear potential to address the underlying biology of fibro-inflammatory diseases and to serve as a scalable, multi-indication platform with disease-modifying potential."

About Pulmonary Fibrosis1,2,3,4,5

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring of lung tissue, leading to declining respiratory function and premature mortality. IPF carries a poor prognosis, with median survival estimated at approximately three to five years from diagnosis, highlighting the urgent need for more effective therapies.

Epidemiological studies and recent systematic reviews indicate that the incidence and prevalence of IPF are increasing worldwide, driven in part by aging populations and improved diagnostic awareness. Current estimates suggest an incidence of several cases per 100,000 persons per year, with prevalence rising substantially in older age groups, placing a growing burden on patients and healthcare systems.

Despite the availability of approved antifibrotic therapies, treatment options remain limited and primarily slow disease progression without reversing fibrosis and are often associated with tolerability challenges. As a result, pulmonary fibrosis represents a significant unmet medical need and a rapidly expanding therapeutic market, reinforcing the importance of developing disease-modifying therapies that can more effectively target the underlying fibro-inflammatory drivers of disease.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to fibroinflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.
About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com

References

1.

Golchin N, Patel A, Scheuring J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis. BMC Pulmonary Medicine. 25:378, 2025.

2.

Lederer DJ, and Martinez FJ. Idiopathic Pulmonary Fibrosis. N ENGL J MED, 378: 1811-23, 2018

3.

Chang A, Ry PM and Raghu G. Idiopathic pulmonary fibrosis: aligning murine models to clinical trials in humans. The Lancet Respiratory Medicine 11: P953-955, 2023.

4.

Marinescu D, Wong AW. Epidemiology of idiopathic pulmonary fibrosis: opportunities and hurdles for population-level studies of rare disease. Thorax 2024;79:603-604.

5.

Maher TM. Interstitial Lung Disease, A Review. JAMA, 331(19): 1655-1665, 2024.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above "About Devonian" paragraph, all of which essentially describes the Company's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws (collectively, "forward-looking statements"), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as "intends", "believes", "expects", or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", or "will" be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Devonian Health Group Inc.

Expansion Plans Set for JOURNY Channel Across India, Southeast Asia and Australia/New Zealand SANTA FE, NEW MEXICO / ACCESS Newswire / February 10, 2026 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a technology-forward media and travel company defining the intersection of Media and Travel, today provided shareholders with an update on progress related to its previously announced joint venture with KC Global Media , which is focused on launching and scaling the JOURNY Channel across India, Southeast Asia ("SEA"), and Australia/New Zealand ("ANZ"), the international expansion of JOURNY, and the recent closing of its acquisition of the GoUSA travel channel and content. KC Global Media has now transitioned into the distribution and marketing phase of the launch across India, SEA, and ANZ.

Paramount Skydance said Tuesday it has sweetened its offer for Warner Bros. Discovery, adding a so-called "ticking fee" to signal regulatory confidence among other new elements.

Paramount stopped short, however, of raising its per-share offer to WBD shareholders. In December, Paramount launched a hostile tender offer for the entirety of Warner Bros. Discovery at $30 per share, all cash. The company argues its offer is superior to a pending transaction between Warner Bros. Discovery and Netflix.

"The additional benefits of our superior $30 per share, all-cash offer clearly underscore our strong and unwavering commitment to delivering the full value WBD shareholders deserve for their investment," said Paramount CEO David Ellison in a statement. "We are making meaningful enhancements – backing this offer with billions of dollars, providing shareholders with certainty in value, a clear regulatory path, and protection against market volatility."

The "ticking fee" is payable to WBD shareholders for any potential delays in receiving regulatory approval for a Paramount-WBD tie-up.

Paramount has set the fee at 25 cents per share per quarter that the transaction hasn't closed after year-end 2026, "underscoring Paramount's confidence in the speed and certainty of regulatory approval for its transaction," the company said.

The so-called ticking fee is equivalent to roughly $650 million in cash value each quarter for every quarter the deal is not closed past Dec. 31.

In addition, on Tuesday Paramount said it would fund the $2.8 billion termination fee that Warner Bros. Discovery would owe Netflix if that deal were to fall through, and it would also eliminate a potential $1.5 billion refinancing cost of debt.

Paramount said the revised offer — including the ticking fee, funding the termination fee and refinancing — is "fully financed" by $43.6 billion of equity commitments from the Ellison family and RedBird Capital Partners, as well as $54 billion in debt commitments from lenders Bank of America, Citigroup and private equity firm Apollo.

Netflix's proposed acquisition of WBD's streaming and studios assets was estimated to close in 12 to 18 months from when the deal was announced in December. That deal would close after the separation of WBD's TV networks, such as CNN, TBS and Discovery, takes place, which is expected in the third quarter of 2026.

Last month, Netflix amended its own offer for WBD assets to pay $27.75 per share entirely in cash. The initial deal was composed of a combination of cash and stock at an equity value of $72 billion.

Paramount's revised offer leans on antitrust concerns that have been raised by lawmakers and industry insiders since Netflix announced the proposed deal.

Netflix co-CEO Ted Sarandos has publicly noted his confidence in getting the deal approved, most recently in the company's January earnings call with investors. Sarandos said he believed the deal would secure regulatory approval, contending it would preserve jobs at a time of heavy layoffs across media "because this deal is pro-consumer ... pro-innovation, pro-worker."

New "Off the Record" Video Series Provides Raw, Unfiltered Access to Freeride Skiing's Ultimate Competition

, /PRNewswire/ -- GoPro, Inc. (NASDAQ: GPRO) and the Freeride World Tour today announced a new mini-series titled "Off the Record" offering fans a behind-the-scenes look at the Freeride World Tour 2026 season. GoPro is the official camera of the Freeride World Tour (FWT) and has served as the tour's exclusive camera partner for more than a decade.

GoPro’s partnership with the Freeride World Tour has gone full-throttle in 2026 with the launch of a new GoPro x FWT mini-series Off the Record, hosted exclusively on the GoPro Snow YouTube channel. In each episode, fans get a behind the scenes look at the Freeride World Tour 2026 season. Catch every episode of Off The Record on the GoPro Snow YouTube channel, with new episodes dropping the week after each Freeride World Tour stop. Shot on HERO13 Black Ultra Wide Edition and GoPro MAX2 360 cameras, Off the Record takes fans behind the scenes to experience the athletes' tension before their runs, the bonds and emotional support the athletes provide one another and the authentic moments that shape the sport few get to see.

"After more than a decade of partnership, GoPro continues to push how freeride is experienced by fans around the world," said Nicolas Hale-Woods, Founder & CEO of the Freeride World Tour. "Off the Record showcases the raw emotion, creativity and commitment that make the Freeride World Tour so special."

Each episode places the athletes at the center of the story, showcasing the preparation, pressure, and passion required to compete at freeride skiing's highest level. Shot from the athletes' point of view, the series brings viewers inside the live experience of freeride. With rare behind-the-scenes access, viewers get to see what usually stays off camera: the travel, the training and the immersed dynamics within the team.

Featured athletes include:

Justine Dufour-Lapointe, competing in FWT's Ski Women for Canada. As a gold and silver medalist mogul skier turned freeride powerhouse, Justine is chasing a FWT threepeat after taking the titles in 2024 and 2025. Marcus Goguen, representing Canada in FWT's Ski Men and the 2025 FWT Champion. Known as a fearless young gun, Marcus brings an aggressive style and a willingness to throw big tricks, all in the pursuit of the podium. Max Hitzig, representing Germany in FWT's Ski Men. With his creative line choices, the 2024 FWT Champion is redefining what it means to ride with passion and creativity at the highest level of freeride skiing. "Our athletes live and breathe this sport every day, not just during their runs," said Rick Loughery, Senior Vice President of Global Marketing and Digital Commerce at GoPro. "Off the Record captures the human side of freeride skiing, and GoPro's cameras put fans right there with them—on the mountain, behind the scenes and inside the moments that define a season."

Watch the first two episodes of Off the Record featuring the Baqueira Beret and Val Thorens tour stops and catch every episode on the GoPro Snow YouTube channel, with new episodes dropping each week after every FWT stop. Subscribe to GoPro Snow on YouTube and follow GoPro Snow on Instagram to learn when each episode drops.

About GoPro, Inc.
GoPro helps the world capture and share itself in immersive and exciting ways.

Connect with GoPro on Instagram, YouTube, TikTok, Facebook, X, LinkedIn, and GoPro's blog, The Current. Members of the press can access official logos and imagery on our press portal. For more information, visit GoPro.com.

GoPro, HERO and their respective logos are trademarks or registered trademarks of GoPro, Inc. in the United States and other countries.

About FWT
FWT Management SA is based in Verbier, Switzerland, and has been organizing premier sports events globally in mountain resorts since 1996. The company founded the Xtreme Verbier, an iconic event in freeride skiing and snowboarding and, in 2008, it turned this single competition into a prestigious series of worldwide events, called the Freeride World Tour (FWT). The company has since grown to include multiple competition series that fall under the FWT brand – including FWT Challenger, FWT Qualifier and FWT Junior – with events across all formats taking place in Europe, North America, South America and Oceania. Since December 2022, FWT is part of the International Ski and Snowboard Federation (FIS). Discover more at www.freerideworldtour.com.

SOURCE GoPro, Inc.

, /PRNewswire/ -- Terex Corporation (NYSE: TEX) today announced the successful sale of Midwest Automotive Designs ("Midwest") to Alliance RV, LLC.  Previously, Midwest operated within the Recreational Vehicles segment of REV Group. Terex recently completed its merger with REV Group.

About Terex

Terex Corporation is a global leader in specialized equipment solutions, serving essential sectors such as emergency services, waste and recycling, utilities, and construction. Our diversified portfolio positions us in resilient, high-demand markets with strong long-term growth potential.

We design and manufacture advanced specialty vehicles—including fire, ambulance, and recreational vehicles—alongside waste collection vehicles, materials processing machinery, mobile elevating work platforms, and equipment for the electric utility industry. Through our global dealer, parts and service network and true value-creating digital solutions, we deliver best-in-class lifecycle support, helping customers maximize return on investment.

With a strong manufacturing footprint in the United States and operations across Europe, India, and Asia Pacific, Terex combines global reach with local expertise to capture opportunities worldwide. Our strategy is clear: exceed customer expectations, invest in innovation, leverage our diversified portfolio, and deliver consistent, profitable growth for our shareholders.

For more information, please visit www.terex.com.

Contact

Derek Everitt
VP, Investor Relations
[email protected]
203-216-8524

SOURCE Terex Corporation

Trimble Navigation (TRMB - Free Report) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.89 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.98%. A quarter ago, it was expected that this GPS manufacturer would post earnings of $0.72 per share when it actually produced earnings of $0.81, delivering a surprise of +12.5%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Trimble, which belongs to the Zacks Manufacturing - General Industrial industry, posted revenues of $969.8 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.00%. This compares to year-ago revenues of $983.4 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Trimble shares have lost about 14.6% since the beginning of the year versus the S&P 500's gain of 1.7%.

What's Next for Trimble?While Trimble has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Trimble was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.72 on $889.41 million in revenues for the coming quarter and $3.44 on $3.82 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Manufacturing - General Industrial is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Watsco (WSO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on February 17.

This heating and cooling company is expected to post quarterly earnings of $1.94 per share in its upcoming report, which represents a year-over-year change of -18.1%. The consensus EPS estimate for the quarter has been revised 8.6% lower over the last 30 days to the current level.

Watsco's revenues are expected to be $1.61 billion, down 8.3% from the year-ago quarter.

Harley-Davidson (HOG - Free Report) came out with a quarterly loss of $2.44 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $0.93 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -165.22%. A quarter ago, it was expected that this motorcycle maker would post earnings of $1.38 per share when it actually produced earnings of $3.1, delivering a surprise of +124.64%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Harley-Davidson, which belongs to the Zacks Automotive - Domestic industry, posted revenues of $390.55 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 25.93%. This compares to year-ago revenues of $430.89 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Harley-Davidson shares have lost about 1.7% since the beginning of the year versus the S&P 500's gain of 1.7%.

What's Next for Harley-Davidson?While Harley-Davidson has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Harley-Davidson was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.20 on $1.14 billion in revenues for the coming quarter and $2.19 on $3.8 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Domestic is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Rivian Automotive (RIVN - Free Report) , is yet to report results for the quarter ended December 2025. The results are expected to be released on February 12.

This a manufacturer of motor vehicles and passenger cars is expected to post quarterly loss of $0.69 per share in its upcoming report, which represents a year-over-year change of -32.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Rivian Automotive's revenues are expected to be $1.26 billion, down 27.4% from the year-ago quarter.

In the early stages of 2026, small-cap stocks are one of the most resurgent asset classes. Equities residing in the small-cap value box are making significant leadership contributions.

Small-cap value leadership is benefiting investors of the O’Shares U.S. Small-Cap Quality Dividend ETF (OUSM). Although it’s not a dedicated small value fund, it is up more than 8% year-to-date. Rather than a strict emphasis on low price-to-book or price-to-earnings ratios, OUSA emphasizes quality, low volatility and, of course, dividends.

On their own, each of those factors has some value traits. A combination of the three enhances the value proposition. That’s working to the benefit of OUSM investors this year. Indeed, there could be more upside on the horizon for the ETF.

OUSM Has Tailwinds Small-cap value stocks are soaring, but OUSM’s cost of admission remains undemanding.

“Despite inching closer to their fair value in recent months, small-value stocks remain the most undervalued part of the style box,” noted Bella Albrecht of Morningstar. “The segment trades at a 10% discount and has spent close to the entirety of the past eight years in undervalued territory. Small-value stocks briefly slipped into overvalued territory in February 2021, but valuations reversed by October and continued to fall, bottoming out at a 35% discount in September 2022.”

That point is particularly important when evaluating OUSM. This ETFs’ holdings should command premium valuations, because dividends aren’t common in the small-cap space. Additionally, many OUSM member firms are profitable at a time when many basic small-cap indexes house scores of money-losing companies.

OUSM could be coming into view for advisors and investors this year. That’s because, as Morningstar noted, small-cap value trailed the broader market for years while large-cap growth led the way. If market breadth widens or investors opt to reduce exposure to growth stocks while remaining invested, small-cap value and ETFs such as OUSM could be logical beneficiaries.

“Small value sits definitionally farthest from large growth, so it’s intuitive that as large growth led the market higher, small value was the most disconnected,” added Albrecht. “As small-cap stocks underperform and valuations fall, they may be reclassified into the value category faster than their fair value estimates can be adjusted.”

For more news, information, and analysis, visit the ETF Building Blocks Content Hub.

VettaFi LLC (“VettaFi”) is the index provider for OUSM, for which it receives an index licensing fee. However, OUSM is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of OUSM.

Earn free CE credits and discover new strategies

A new year brings renewed upside for uranium, especially given the strategic tailwinds behind the metal, according to a Sprott Uranium Report from Sprott Asset Management’s Director of ETF Product Management Jacob White.

As White noted, the uranium market entered 2026 with strong momentum. 2025’s focus on artificial intelligence (AI) created fundamental drivers for nuclear power as a viable energy source. That energy will be vital, given the current and forthcoming energy demand that AI requires. White noted that uranium climbed back into triple digits during the month of January, reaching $101.26 per pound to notch a 24% increase in a single month. From a technical standpoint, uranium’s price is moving past previous resistance levels thanks to tightening supply and increased strategic demand.

“Uranium demand is becoming increasingly visible, driven by energy security, electrification, and the need for reliable baseload power amid rising electricity demand,” White said.

U.S. Policy Support Uranium’s status as a “critical material” is gaining further U.S. policy support, which should provide additional tailwinds. White mentioned a Section 232 proclamation that deemed current import levels as a potential threat to the national security of the United States. As such, the U.S. can negotiate with trading partners to adjust these import levels.

“The proclamation explicitly includes uranium in its description of the energy sector’s reliance on critical minerals for nuclear fuel, and it frames the vulnerability as overreliance on foreign supply chains, limited, secure and reliable access, and price volatility that can deter investment and weaken domestic capability,” White said. He mentioned that Section 232 is important because of the price optionality it brings to uranium with regard to any negotiations with trade partners.

“If negotiations ultimately result in measures that raise the effective price of securing uranium supply in the U.S., uranium could be pulled into a higher-incentive price framework,” White added. “A higher price would improve project economics and strengthen the long-term price visibility that underpins mine restarts and new development.”

Mining Opportunities As White also highlighted in the report, the uranium market remains in a structural deficit. Major producers have tightened exploration controls while global production continues to lag behind demand. To exacerbate the supply deficit further, the World Nuclear Association is forecasting that reactor requirements will more than double by 2040. That further supports the case for new mines.

Given these factors, one fund to consider is the Sprott Uranium Miners ETF (URNM). URNM provides exposure to both physical uranium and its miners. It allows investors to add targeted commodities exposure to an existing portfolio in the ease of an ETF wrapper. URNM could also complement a growth-focused portfolio by adding commodities diversification.

For more news, information, and analysis, visit the Gold/Silver/Critical Minerals Content Hub.

An investor should consider the investment objectives, risks, charges, and expenses carefully before investing. To obtain a Prospectus, which contains this and other information, contact your financial professional or call 888.622.1813. Read the Prospectus carefully before investing, which can also be found by clicking one of the links below.

Past performance is no guarantee of future results.  One cannot invest directly in an index.

Funds that emphasize investments in small/mid-cap companies will generally experience greater price volatility. Diversification does not eliminate the risk of investment losses. ETFs are considered to have continuous liquidity because they allow an individual to trade throughout the day. A higher portfolio turnover rate may indicate higher transaction costs and may result in higher taxes when Fund shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses, affect the Fund’s performance.

Sprott Asset Management USA, Inc. is the Investment Adviser to the ETFs. ALPS Distributors, Inc. is the Distributor for the ETFs and is a registered broker-dealer and FINRA Member. ALPS Distributors, Inc. is not affiliated with Sprott Asset Management USA, Inc. or VettaFi.

Exchange Traded Funds (ETFs): SETM, LITP, URNM, URN, COPP, COPJ, NIKL, SGDM, SGDJ, SLVR, GBUG, METL
Physical Bullion Funds:PHYS, PSLV, CEF, and SPPP.

Gold and precious metals are referred to with terms of art like store of value, safe haven and safe asset. These terms should not be construed to guarantee any form of investment safety. While “safe” assets like gold, Treasuries, money market funds and cash generally do not carry a high risk of loss relative to other asset classes, any asset may lose value, which may involve the complete loss of invested principal.

Earn free CE credits and discover new strategies

Acquisition Facility expected to accelerate asset acquisition strategy

Fort Worth, TX, Feb. 10, 2026 (GLOBE NEWSWIRE) --   Presidio Investment Holdings LLC (“Presidio” or the “Company”), a differentiated oil and gas operator focused on the acquisition and optimization of mature, producing oil and natural gas assets in the United States, and EQV Ventures Acquisition Corp. (NYSE: FTW) ("FTW"), a special purpose acquisition company sponsored by EQV Group, today announced that Presidio has mandated an affiliate of Goldman Sachs (NYSE: GS) to arrange up to $1.0 billion  in potential acquisition financing for Presidio following the completion of its business combination.

Goldman Sachs Bank USA with one or more of its affiliates is expected to serve as sole lead arranger, structuring agent and syndication agent in up to $1.0 billion of potential acquisition financing (the “Facility”). The parties have reached commercial agreement on certain high-level terms for the Facility. The closing of the Facility remains subject to the negotiation and execution of terms and definitive transaction agreements, future acquisitions of producing properties, and is subject to acquisition diligence and funding and other relevant approvals, and customary closing conditions.

The Facility is expected to provide Presidio with significant capital flexibility to pursue acquisitions of producing oil and gas assets. The Facility is designed to support the aggregation of assets prior to issuing long-term investment grade asset-backed securities, which may be used to repay such Facility. Presidio intends to deploy the Facility to drive dividend growth and long-term shareholder returns by acquiring producing, cash-flowing assets and harvesting meaningful upside through Presidio’s strategy of operational optimization. Presidio’s business model drives value through the application of modern oilfield practices, proprietary technology including machine learning and AI, and strategic consolidation.

“Presidio pioneered the use of ABS to fund producing oil and gas assets at scale—paving the way for the billions of ABS energy issuances since then—and is now pleased about the opportunity to mandate Goldman Sachs to help us innovate further in the space. This new financing structure is intended to be used at the signing of future acquisitions, allowing us to demonstrate surety of funding to sellers, at an attractive cost of capital for Presidio. We believe this will enable us to capture more producing assets than we expected and enhance returns on equity,” said Will Ulrich, Co-Founder and co-CEO of Presidio. “Goldman Sachs brings deep experience across energy investing, commodity based structured capital solutions, and asset-backed financing. We are delighted to work with them to accelerate our growth."

Chris Hammack, Co-Founder and co-CEO of Presidio, continued, “we have an incredible track record of creating value by acquiring and optimizing producing oil and gas assets. I am excited to implement both our existing optimization experience and new AI driven workflows to create shareholder value. This proposed financing facility has the potential to provide capital to enhance our scale, so we can create alpha on new acquisitions.”

Rationale for the Facility:

Working with world-class, industry leading bank experienced in securitizations and commodity-based capital solutionsExpected to provide committed financing upon signing future acquisitions of producing properties allowing for seller confidence in closing with an attractive cost of capital for the CompanyLow-cost debt financing allows for future potential dividend increases from acquisitionsFlexibility to optimize timing of future long-term investment grade Asset-Backed Security financing Business Combination Update

On January 30, 2026, the registration statement on Form S-4 relating to the previously announced business combination (the “Business Combination”) between EQV and Presidio was declared effective by the U.S. Securities and Exchange Commission. EQV shareholders will vote on the proposed business combination at an extraordinary general meeting scheduled for February 27, 2026, with the combined entity expected to trade on the New York Stock Exchange under the ticker symbol "FTW" upon closing.

About Presidio

Headquartered in Fort Worth, TX, Presidio is a leading operator of mature oil and gas wells across the Mid-Continent. The company is focused exclusively on optimizing existing production and generating sustainable cash flow from low-decline, producing assets. To learn more about Presidio, please visit https://bypresidio.com/.

About EQV Ventures Acquisition Corp.

EQV Ventures Acquisition Corp. (NYSE: FTW) is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. EQV’s sponsor is an affiliate of EQV Group, which was formed in 2022 and is an active acquirer and operator of proved developed producing oil and gas properties, and currently owns and operates more than 3,500 wells across 10 states.

About the Facility

Entry into the Facility is subject to consummation of the Business Combination, the negotiation of definitive documentation and additional approvals by the parties thereto.   Any future acquisitions and associated capital commitments under the Facility will be subject to customary due diligence, approvals and additional documentation between Presidio and Goldman Sachs.  There is no guarantee that the Facility will be entered into on the foregoing terms or at all.

About Goldman Sachs

Goldman Sachs is a leading global financial institution that delivers a broad range of financial services to a large and diversified client base that includes corporations, financial institutions, governments and individuals. Founded in 1869, the firm is headquartered in New York and maintains offices in all major financial centers around the world.

Forward-Looking Statements

This press release includes “forward-looking statements.” These include EQV’s, Presidio Pubco Inc.’s (“Pubco”), EQVR’s or Presidio’s or their management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “potential,” “budget,” “may,” “will,” “could,” “should,” “continue” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Pubco’s, Presidio’s, EQVR’s and EQV’s expectations with respect to future performance, the negotiation of definitive documentation regarding the Facility on the anticipated terms, the capitalization of EQV or Pubco after giving effect to the proposed Business Combination and expectations with respect to the future performance and the success of Pubco following the consummation of the proposed Business Combination, including Pubco’s ability to consummate acquisitions and the realization of the benefits of such acquisitions. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Pubco’s, Presidio’s, EQVR’s and EQV’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied upon by any investors as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Pubco, Presidio, EQVR and EQV. These forward-looking statements are subject to a number of risks and uncertainties, including changes in business, market, financial, political and legal conditions; benefits from hedges and expected production; the inability of the parties to successfully or timely consummate the proposed Business Combination, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Pubco or the expected benefits of the proposed Business Combination or that the approval of the shareholders of EQV is not obtained; the inability of Pubco to negotiate definitive documentation and enter into the Facility on the anticipated terms or at all; failure to realize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of Pubco to grow and manage growth profitably, maintain key relationships and retain its management and key employees; risks related to the uncertainty of the projected financial information with respect to Presidio or Pubco; risks related to Presidio’s current growth strategy; the occurrence of any event, change or other circumstances that could give rise to the termination of any definitive agreements with respect to the proposed Business Combination; the outcome of any legal proceedings that may be instituted against any of the parties to the potential Business Combination following its announcement and any definitive agreements with respect thereto; changes to the proposed structure of the proposed Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the proposed Business Combination; risks that Presidio or Pubco may not achieve their expectations; the ability to meet stock exchange listing standards following the proposed Business Combination; the risk that the proposed Business Combination disrupts the current plans and operations of Presidio; costs related to the potential Business Combination; changes in laws and regulations; risks related to the domestication of EQV as a Delaware corporation; risks related to Pubco’s ability to pay expected dividends; the extent of participation in rollover agreements; the amount of redemption requests made by EQV’s public equity holders; and the ability of EQV or Pubco to issue equity or equity-linked securities or issue debt securities or enter into debt financing arrangements in connection with the proposed Business Combination or in the future. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by Presidio, EQV, EQVR or Pubco resulting from the proposed Business Combination with the SEC, including under the heading “Risk Factors” in the Registration Statement. If any of these risks materialize or any assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that none of Pubco, Presidio, EQVR nor EQV presently know or that Pubco, Presidio, EQVR or EQV currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by investors as a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

In addition, forward-looking statements reflect Pubco’s, Presidio’s, EQVR’s and EQV’s expectations, plans or forecasts of future events and views as of the date they are made. Pubco, Presidio, EQVR and EQV anticipate that subsequent events and developments will cause Pubco’s, Presidio’s, EQVR’s and EQV’s assessments to change. However, while Pubco, Presidio, EQVR and EQV may elect to update these forward-looking statements at some point in the future, Pubco, Presidio, EQVR and EQV specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Pubco’s, Presidio’s, EQVR’s or EQV’s assessments as of any date subsequent to the date they are made. Accordingly, undue reliance should not be placed upon the forward-looking statements. None of Pubco, Presidio, EQVR or EQV, or any of their respective affiliates have any obligation to update these forward-looking statements other than as required by law.

Additional Information and Where to Find It

In connection with the proposed Business Combination, Pubco, EQVR and Presidio filed the Registration Statement with the SEC, which includes a prospectus with respect to Pubco’s securities to be issued in connection with the proposed Business Combination and a proxy statement with respect to the shareholder meeting of EQV to vote on the proposed Business Combination. EQV, Pubco, EQVR and Presidio also plan to file other documents and relevant materials with the SEC regarding the proposed Business Combination. The Registration Statement was declared effective by the SEC on January 30, 2026. Mailing of the definitive Proxy Statement/Prospectus to EQV’s shareholders of record as of January 30, 2026 commenced on January 30, 2026. The Proxy Statement/Prospectus includes information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to EQV’s shareholders in connection with the proposed Business Combination. SECURITY HOLDERS OF EQV AND OTHER INTERESTED PARTIES ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS AND RELEVANT MATERIALS RELATING TO THE PROPOSED BUSINESS COMBINATION THAT HAVE BEEN AND WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED BUSINESS COMBINATION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION. Shareholders are able to obtain free copies of the Proxy Statement/Prospectus and other documents containing important information about Pubco, Presidio, EQVR and EQV once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by EQV may be obtained free of charge from EQV at www.eqvventures.com. Alternatively, these documents, when available, can be obtained free of charge from EQV or Pubco upon written request to EQV Ventures Acquisition Corp., 1090 Center Drive, Park City, Utah, 84098, Attn: Secretary, or by calling (405) 870-3781. The information contained on, or that may be accessed through the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

EQV, Presidio, EQVR, Pubco and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of EQV in connection with EQV’s shareholder meeting. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of EQV’s executive officers and directors in the solicitation by reading EQV’s annual report on Form 10-K, filed with the SEC on March 31, 2025, the definitive Proxy Statement/Prospectus, filed with the SEC on January 30, 2026, the Registration Statement and other relevant materials filed with the SEC in connection with the proposed Business Combination when they become available. Information concerning the interests of EQV’s participants in the solicitation, which may, in some cases, be different from those of EQV’s shareholders generally, is set forth in the definitive Proxy Statement/Prospectus and the Registration Statement.

No Offer or Solicitation

This press release shall not constitute a solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of EQV, PIH, EQVR or Pubco, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. This press release is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction in where such distribution or use would be contrary to local law or regulation.

Presidio Media and Investor Contact:

[email protected]

For EQV:
[email protected] 

Source: EQV Ventures Acquisition Corp.

– Reinforces Trinity Biotech’s growing position as a key player in diabetes care innovation

– Senior commercial executives of Trinity Biotech are attending the World Health Expo from February 10-12, 2026

DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that its Premier Hb9210™ HbA1c Analyser with its recently launched next-generation Buffer A Plus column system has achieved the prestigious Gold Classification from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) for 2026. This marks a historic milestone as the Premier Hb9210™ HbA1c Analyser is the only HbA1c system worldwide to earn this highest level of HbA1c manufacturer's certification for 2026. 

No system achieved Gold status in 2025, underscoring the significance of Trinity Biotech’s breakthrough. This achievement demonstrates the company’s ability to deliver industry-leading technology innovations that advance diabetes care worldwide.

The next-generation Premier Hb9210™ Buffer A Plus column system, which is used for laboratory testing, builds on a series of recent innovations and enhancements to the Premier Hb9210™ platform, designed to increase usability, minimize operator interaction, and reduce operating costs while continuing to support the highest levels of patient care.

The IFCC is the global authority that sets international standards for HbA1c measurement, a critical biomarker for blood glucose management in diabetes care. HbA1c reflects the average blood glucose level over the past 2–3 months.  The IFCC’s rigorous certification process evaluates more than 200 HbA1c analytical systems from approximately 60 manufacturers, including the largest global diagnostic companies. Systems are ranked based on analytic precision and bias, with Gold representing the pinnacle of performance.

The global market for laboratory HbA1c testing is currently valued at over $2 billion per year and is projected to surpass $3.5 billion by 20301. This anticipated growth is largely due to the rising incidence of diabetes. Senior commercial executives of Trinity Biotech are attending the World Health Expo from February 10-12, 2026 to discuss these and other advancements that strengthen Trinity Biotech’s position in the expanding $2 billion HbA1c testing market.  

_____________________________

1 https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/

Management Commentary

John Gillard, Trinity Biotech CEO, commented:

“Achieving IFCC Gold Classification is a testament to our core focus on industry-leading innovation, precision, and quality at Trinity Biotech. It further enhances our standing in the broader glucose monitoring market and diabetes care where we already support millions of patients around the world annually with our HbA1c testing technology.

We are deeply committed to diabetes care and broader metabolic health management, with Trinity Biotech’s cumulative investment in our diabetes care technologies already approaching approximately $100 million to date. Central to this commitment is the pioneering development of our continuous glucose monitoring innovation, CGM+ that is being designed to augment glucose monitoring with other metabolic health metrics in a single AI-powered device.

With several exciting R&D milestones anticipated over the course of this year, we are advancing strongly in our mission to help everyone measure and manage metabolic health for healthier, longer lives.”

For more information about Trinity Biotech and the Premier Hb9210™ system, please contact [email protected]

Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

Contact:Trinity Biotech plcRedChip Companies Inc. Gary Keating, Ph.DDave Gentry, CEO (353)-1-2769800(1)-407-644-4256  (1)-800-RED-CHIP (733-2447)  [email protected]

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA) ("Tartisan", or the "Company") is pleased to announce that the Company has acquired eleven additional claims in the Turtle Pond Area, approximately 40 kms south of Dryden, Ontario and approximately 70 kms east of the Company's flagship Kenbridge Nickel-Copper-Cobalt Project.

The total property package now consists of 161 claims covering 3,375 ha. The claims are owned 100% by Tartisan Nickel Corps. wholly owned subsidiary Canadian Arrow Mines Limited. The property is situated in an area with excellent infrastructure.

Previous exploration efforts identified nickel-copper sulphide mineralization in twelve trenches along a 700-metre trend at the Glatz nickel copper showing. The zone, discovered in 1965 by local prospector A. Glatz, is up to 40 metres wide and is open along strike and at depth. Historical grab samples were reported to contain up to 1.95% Ni. In 2007, Canadian Arrow Mines Limited conducted a surface grab sampling program which produced the following results: 1.28% Ni, 0.26% Cu re Glatz Trench 3; 0.99% Ni, 0.18% Cu re Glatz Trench 3; 0.39% Ni, 4.06% Cu re Trench 4. The mineralization varies from disseminated sulphides to narrow semi-massive sulphide bands. Six short drill holes were completed at that time with hole GZ-09- 02 encountering 0.34% Ni, 0.16% Cu and 0.02% Co over 5.9 m from 45.0-50.9 m.

A nickel-copper-PGE discovery on the Double E airborne VTEM anomaly was identified in 2008. The drilling intersected two separate upper and lower mineralized zones in 2 drill holes. Hole EE-09-02 intersected 4.2 metres of 0.81% Ni, 0.52% Cu, 0.20gpt Pt, 0.16gpt P and 0.20gpt Au at a depth of 25.5 metres. This included 2 metres of 1.35% Ni, 0.81% Cu, 0.36gpt Pt, 0.27gpt Pd and 0.31gpt Au. A second zone was intersected at a depth of 135.1 metres containing 8.2m of 0.55% Ni and 0.38% Cu. Hole EE-l0-04 intersected 1.9 metres of 0.51% Ni, 0.24% Cu at a depth of 21.4 metres and a second narrow intersection of 1.9 metres of 0.52% Ni, 0.28% Cu at a depth of 28 metres.

Exploration diamond drilling work completed in 2009 and 2010 on the Night Danger nickel-copper reported a nine-metre-wide section of stringers and blebs of sulphide which assayed 0.57% Ni and 0.45% Cu at a drill depth of 79m in hole ND-09-1. Two sections within this interval assayed greater than 1% nickel. Drill hole ND-10-1 intersected 4.53% Ni over 0.7m at a drill depth of 57.5m (Source; MNDM assessment files and Canadian Arrow Mines Limited news release dated June 1, 2010, SEDAR).

From November 28th to December 21st, 2024, a TDEM Geophysical survey was performed on the Turtle Pond Property undertaken by Expert Geophysics Limited (SEDAR+ February 27, 2025). Tartisan Nickel Corp. conducted this survey for the purpose of determining drill targets and potential future exploration work on the Turtle Pond Project.

Mark Appleby, President and CEO of Tartisan stated "The Glatz, Double E and Night Danger nickel-copper showings display similar nickel and copper tenors as what we find near surface at our Kenbridge Nickel-Copper-Cobalt Project. Acquisition of these claims complement the company's larger objective of developing the Kenbridge Nickel-Copper-Cobalt Project into an operating mine with a central milling facility. The Company will be formulating an exploration program consisting of surface sampling and potentially diamond drilling for 2026-27.

Figure 1: Location and Regional Geology of the Turtle Pond Project and Kenbridge Ni-Cu-Co Project

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/1492/283392_1697a81eb4639a70_002full.jpg

Figure 2. Turtle Pond: Night Danger, Glatz, Double E property outline and Historical Mineral Showings

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/1492/283392_1697a81eb4639a70_003full.jpg

Qualified Person

The technical information in this news release has been prepared in accordance with Canadian regulatory requirements as set out in NI 43-101 and reviewed and approved by Dean MacEachern, P. Geo., an Independent Consultant to the Company and a Qualified Person as defined by NI 43-101.

About Tartisan Nickel Corp.

Tartisan Nickel Corp. is a Canadian-based critical minerals exploration and development company which owns, the Kenbridge Nickel Project near Sioux Narrows, Northwestern Ontario, the Sill Lake Silver Project near Sault Ste. Marie, Ontario as well as the Night Danger, Glatz Turtle Pond Project near Dryden, Ontario.

Tartisan Nickel Corp. common shares are listed on the Canadian Securities Exchange (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA). Currently, there are 152,215,641 shares issued and outstanding (156,287,356 fully diluted).

For further information, please contact Mark Appleby, President & CEO, and a Director of the Company, at 416-804-0280 ([email protected]). Additional information about Tartisan Nickel Corp. can be found at the Company's website at www.tartisannickel.com or on SEDAR at www.sedarplus.ca.

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283392

Source: Tartisan Nickel Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease
Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designation
This appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team
LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer. Dr. Mantelli brings unparalleled experience in ocular surface drug development, having led the clinical development, regulatory approval, and global medical strategy of Oxervate® (cenegermin-bkbj) at Dompé farmaceutici S.p.A. which achieved blockbuster status with sales topping $1 billion in 2024 and is widely considered one of the most successful orphan drug launches in ophthalmology.

Dr. Mantelli is a highly regarded ophthalmologist with an extensive background in cornea and ocular surface diseases, neurotrophic keratopathy, and inflammatory eye conditions. He brings critical knowledge and experience to OKYO in developing therapeutics from first-in-human studies through to global regulatory approval. As the clinical leader behind the transformation of a novel biologic into a first-in-class, FDA approved topical ophthalmic therapy, he set a new benchmark for orphan drug clinical development for treatments of corneal disease. Dr. Mantelli graduated in Medicine and Surgery summa cum laude from Università Campus Bio-Medico of Rome, where he also completed his residency in ophthalmology and a PhD in regenerative medicine. He further pursued a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute, Harvard Medical School.

In his new role at OKYO Pharma, Dr. Mantelli will oversee the company's clinical development strategy, including the advancement of urcosimod in planned clinical trials for neuropathic corneal pain and additional orphan indications. He intends to build upon the recent FDA alignment with the proposed Phase 2b/3 design, to help ensure the upcoming trial is positioned as a potential pivotal study to bring this important therapy to patients with no FDA approved therapy.

“Neuropathic corneal pain represents one of the most debilitating and underserved areas in ophthalmology. OKYO Pharma’s focus on differentiated, mechanism-based approaches to inflammatory eye diseases and neuropathic corneal pain resonates strongly with my career-long dedication to translating breakthrough science into approved innovative therapies. The fast-track designation and the recent authorization for compassionate use by FDA for urcosimod in NCP highlights the urgency and potential in this area of high unmet medical need,” said Flavio Mantelli, MD, PhD, Chief Medical Officer of OKYO Pharma. “I am excited to join OKYO and work alongside Robert Dempsey and the entire team to advance urcosimod and the broader portfolio, seeking to ensure our development strategy remains grounded in strong science, regulatory rigor, and a clear focus on improving outcomes for patients and eyecare providers.”

“Subsequent to the release of our Phase 2 data in neuropathic corneal pain, OKYO Pharma has attracted two exceptional leaders in ophthalmology, commencing with the appointment of our CEO, Robert Dempsey, and followed by today’s appointment of Dr. Flavio Mantelli as our Chief Medical Officer,” said Gabriele Cerrone, Chairman and Founder of OKYO Pharma. “Dr. Mantelli’s clinical leadership role and experience in developing Oxervate® into a blockbuster drug with annual sales exceeding $1 billion for a rare eye disease, will be invaluable for OKYO’s development of urcosimod for patients with NCP.”   

“Bringing Dr. Mantelli into the executive team is tremendously important as we continue to build a world class organization focused on ocular surface disease,” said Robert Dempsey, CEO of OKYO Pharma. “Dr. Mantelli is an exceptional clinical developer whose leadership of a highly successful orphan drug development program in ophthalmology demonstrates his ability to advance complex corneal programs, capabilities that will be critical as we advance urcosimod forward for neuropathic corneal pain.”

As previously announced, urcosimod was granted the first IND application for the treatment of patients with NCP and was awarded fast track designation by the Food and Drug Administration (FDA). The company expects to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

About Flavio Mantelli, MD, PhD

Dr. Mantelli joins OKYO Pharma from Dompé where he served as the Chief Strategy & Innovation Officer, acting as the key link between the company and external partners, with the goal of promoting groundbreaking research initiatives and assessing new opportunities aligned with industry innovations. Previously he served as Chief Medical Officer and Head of R&D for the Ophthalmology and Neurotrophin platforms, leading all research and clinical development programs in ophthalmology.

Prior to joining Dompé, Dr. Mantelli researched the application of neurotrophins in ophthalmic and neurodegenerative diseases and was an adjunct associate professor of biology at Temple University in Philadelphia, PA. His professional experience includes positions at the IRCCS G.B. Bietti Foundation in Rome as a clinical scientist and as a consultant ophthalmologist at the Campus Biomedico University of Rome and the Cornea and Ocular Surface Unit of the Vita-Salute San Raffaele University of Milan. 

Graduating in Medicine and Surgery summa cum laude, Dr. Mantelli completed his residency program in ophthalmology and a PhD at the Campus Bio-Medico University of Rome. He also completed a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute of Massachusetts Eye and Ear at Harvard Medical School in Boston. 

About Neuropathic Corneal Pain (NCP)

Neuropathic corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of corneal sensory nerves, often in combination with inflammatory processes, and may occur in patients with a range of underlying ophthalmic conditions. There are currently no FDA-approved therapies specifically for NCP, resulting in patients being treated with limited or no success using various topical and systemic medications in an off-label manner.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain patients. Urcosimod has shown significant pain reduction in an earlier 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2025. The company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements, except as may be required by law.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cf9ede5-810f-4085-8f70-0818346bb549

Flavio Mantelli, MD, PhD, OKYO Pharma Chief Medical Officer Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development pro...

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - Antimony Resources Corp. (CSE: ATMY) (OTCQB: ATMYF) (FSE: K8J0) (the "Company" or "Antimony Resources" or "ATMY") is pleased to announce that investors have exercised 6,104,400 common share purchase warrants of the Company for gross proceeds of $1,212,704 since November 30, 2025.

With the closing of the $9,450,000 financing announced on December 30, 2025 and the exercise of these warrants, further strengthens the Company's balance sheet. The proceeds will be used for exploration work on the Bald Hill Antimony Project and for working capital purposes.

Bald Hill Antimony Project

Highlights

Bald Hill is a well-known, high-grade antimony deposit in southern New Brunswick, Canada.Drilling has outlined an antimony deposit over 700 m. long.Widths of mineralization average 3 to 4 meters and grades average 3% to 4% antimony.NI-43-101 Technical Report: The estimated potential quantity and grade of the drilled area from the 2025 Technical Report, which is the target of our exploration, is approximately 2.7 million tonnes with a grade between 3% and 4% antimony1. For more details on the Potential of the project as described by the author of the Technical report please consult the NI43-101 which has been filed on SEDAR. Antimony Resources Corp. has not completed enough work to confirm this estimate. The potential quantity and grade are conceptual in nature as there has been insufficient exploration to define a mineral resource, and it is uncertain if further exploration will result in the target being delineated as a mineral resource.Potential to expand based on additional known targets and additional claims added to the property.(1) NATIONAL INSTRUMENT 43-101 TECHNICAL REPORT: BALD HILL ANTIMONY PROJECT SOUTHERN NEW BRUNSWICK, CANADA NTS 21G/09 Prepared for Antimony Resources October 28, 2025. Prepared By John Langton, M.Sc., P. GEO., - JPL GeoServices, Fredericton, New Brunswick, Canada. The technical contents of this news release were reviewed and approved by Jim Atkinson, MSc., P.Geo., President and CEO of Antimony Resources Corp. who is a qualified person as defined by National Instrument 43-101.

About Antimony Resources Corp. (CSE: ATMY) (OTCQB: ATMYF) (FSE: K8J0)

Antimony Resources Corp. is an exploration and development company focused exclusively on Antimony. The Company's management team possesses extensive experience in financing, exploration, development and mining. The Company is focused on becoming a significant North American producer of antimony.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283368

Source: Antimony Resources Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- Burford Capital Limited ("Burford"), the leading global finance and asset management firm focused on law, will release its financial results for the three months ended December 31, 2025 ("4Q25") and the year ended December 31, 2025 ("FY25") on Thursday, February 26, 2026, at 8.00am EST / 1.00pm GMT.

Burford will hold a conference call for investors and analysts at 9.00am EST / 2.00pm GMT on Thursday, February 26, 2026. For swift access to the conference call at the time of the event, pre-registration is encouraged at https://registrations.events/direct/Q4I740130. The dial-in numbers for the conference call are +1 (646) 307-1951 (USA) or +1 (888) 500-3691 (USA & Canada toll free) / +44 (0)20 8610 3526 (UK) or +44 800 524 4258 (UK toll free), and the access code is 74013. To minimize the risk of delayed access, participants are urged to dial into the conference call by 8.40am EST / 1.40pm GMT.

A live audio webcast and replay will also be available at https://events.q4inc.com/attendee/657000184, and pre-registration at that link is encouraged.

An accompanying 4Q25 and FY25 results presentation for investors and analysts will be made available on Burford's website prior to the conference call at http://investors.burfordcapital.com.

For further information, please contact:

Burford Capital Limited

For investor and analyst inquiries:

Americas: Josh Wood, Head of Investor Relations - email

+1 212 516 5824

EMEA & Asia: Rob Bailhache, Head of EMEA & Asia Investor Relations - email

+44 (0)20 3530 2023

For press inquiries:

David Helfenbein, Senior Vice President, Public Relations - email

+1 646 504 7074

Deutsche Numis - NOMAD and Joint Broker

+44 (0)20 7545 8000

Duncan Monteith

Charlie Farquhar

BofA Securities – Joint Broker

+44 (0)20 7628 1000

Peter Luck

David Lloyd

Jefferies International Limited - Joint Broker

+44 (0)20 7029 8000

Graham Davidson

James Umbers

Berenberg – Joint Broker

+44 (0)20 3207 7800

Toby Flaux

James Thompson

About Burford Capital

Burford Capital is the leading global finance and asset management firm focused on law. Its businesses include litigation finance and risk management, asset recovery and a wide range of legal finance and advisory activities. Burford is publicly traded on the New York Stock Exchange (NYSE: BUR) and the London Stock Exchange (LSE: BUR) and works with companies and law firms around the world from its global network of offices.

For more information, please visit www.burfordcapital.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any ordinary shares or other securities of Burford.

This press release does not constitute an offer of any Burford private fund. Burford Capital Investment Management LLC, which acts as the fund manager of all Burford private funds, is registered as an investment adviser with the US Securities and Exchange Commission. The information provided in this press release is for informational purposes only. Past performance is not indicative of future results. The information contained in this press release is not, and should not be construed as, an offer to sell or the solicitation of an offer to buy any securities (including interests or shares in any of Burford private funds). Any such offer or solicitation may be made only by means of a final confidential private placement memorandum and other offering documents.

Forward-looking statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor provided for under these sections. In some cases, words such as "aim", "anticipate", "believe", "continue", "could", "estimate", "expect", "forecast", "guidance", "intend", "may", "plan", "potential", "predict", "projected", "should" or "will", or the negative of such terms or other comparable terminology, are intended to identify forward-looking statements. Although Burford believes that the assumptions, expectations, projections, intentions and beliefs about future results and events reflected in forward-looking statements have a reasonable basis and are expressed in good faith, forward-looking statements involve known and unknown risks, uncertainties and other factors, which could cause Burford's actual results and events to differ materially from (and be more negative than) future results and events expressed, projected or implied by these forward-looking statements. Factors that might cause future results and events to differ include, among others, those discussed in the "Risk Factors" section of Burford's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission on March 3, 2025. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements contained in the periodic and current reports that Burford files with or furnishes to the US Securities and Exchange Commission. Many of these factors are beyond Burford's ability to control or predict, and new factors emerge from time to time. Furthermore, Burford cannot assess the impact of each such factor on its business or the extent to which any factor or combination of factors may cause actual results and events to be materially different from those contained in any forward-looking statement. Given these uncertainties, readers are cautioned not to place undue reliance on Burford's forward-looking statements.

All subsequent written and oral forward-looking statements attributable to Burford or to persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements speak only as of the date of this press release and, except as required by applicable law, Burford undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Burford Capital Limited

Supports the Acquisition and Growth of a Leading Healthcare Benefits Platform and Demonstrates AFC’s Expanded Investment Mandate as a BDC February 10, 2026 08:00 ET  | Source: Advanced Flower Capital

WEST PALM BEACH, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- AFC today announced that it has committed $29 million to a $60 million senior secured term loan.  The proceeds from the credit facility, including $19.6 million funded by AFC at close, will be used to finance the acquisition of a leading healthcare benefits platform (the “Platform”).

“We are excited to support a top-tier sponsor and management team in this transaction. The Platform has developed a comprehensive benefits program tailored toward a large and underserved segment of the workforce,” said Daniel Neville, Chief Executive Officer of AFC. “This transaction underscores our ability to provide flexible, institutional capital to sponsors following our conversion to a BDC earlier this year.”

The credit facility is secured by a lien on all assets of the borrower and has a four-year term. AFC holds approximately 49% of the total facility.

About AFC

AFC (Nasdaq: AFCG) is a publicly traded business development company that provides flexible credit solutions to lower middle market companies. The company primarily originates, structures, invests and manages direct senior debt investments typically ranging from $10 to $100 million. The company seeks to maximize risk-adjusted returns for its stockholders with an opportunistic approach across all industries. AFC is headquartered in West Palm Beach, Florida. For additional information regarding the company, please visit advancedflowercapital.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views and projections with respect to, among other things, future events and financial performance. Words such as “believes,” “expects,” “will,” “intends,” “plans,” “guidance,” “estimates,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements about our future growth and strategies for such growth, are subject to the inherent uncertainties in predicting future results and conditions and are not guarantees of future performance, conditions or results. Certain factors, including the ability of our manager to locate suitable loan opportunities for us, monitor and actively manage our loan portfolio and implement our investment strategy; and other factors could cause actual results and performance to differ materially from those projected in these forward-looking statements. More information on these risks and other potential factors that could affect our business and financial results is included in AFC’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of AFC’s most recently filed periodic reports on Form 10-K, Form 10-Q and subsequent filings. New risks and uncertainties arise over time, and it is not possible to predict those events or how they may affect AFC. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact

Robyn Tannenbaum
561-510-2293
[email protected]

February 10, 2026 08:00 ET  | Source: Septerna, Inc.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from its Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, taking place February 27-March 2, 2026, in Philadelphia. SEP-631 is a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.

Poster Presentation Details:

Title: First-In-Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge
Poster Number: L58
Session: Late Breaking Poster Session II
Session Date and Time: March 1, 2026, 9:45-10:45 a.m. ET
Location: Pennsylvania Convention Center, Level 2, Hall E

About SEP-631
Septerna is developing SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) for the treatment of patients with chronic spontaneous urticaria (CSU) and other mast-cell driven diseases. MRGPRX2 is known to play an important role in mast cell activation and degranulation which, in combination with other inflammatory mediators, lead to debilitating symptoms for patients. In addition to CSU, MRGPRX2 is highly and uniquely expressed on mast cells implicated in multiple diseases, including asthma, atopic dermatitis, interstitial cystitis, and migraine. In preclinical studies, SEP-631 demonstrated potent and long-lasting inhibition of MRGPRX2 and blocked mediator-induced skin extravasation in mice engineered to express the human MRGPRX2 receptor.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
[email protected]

Media Contact:
Carly Scaduto, THRUST
[email protected]

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - Trinity One Metals Ltd. (TSXV: TOM) (FSE: 5D5) (the "Company") is pleased to announce a non-brokered private placement (the "Offering") for the sale of up to 16,500,000 units of the Company (the "Units") at a price of C$0.20 per Offered Unit for gross proceeds of up to C$3,300,000.

Each Unit will consist of one common share of the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder to purchase one Common Share (each, a "Warrant Share") at an exercise price of C$0.30 per Warrant Share for a period of thirty-six (36) months following the closing date of the Offering (the "Closing Date"), provided that the Warrants may not be exercised for a period of sixty (60) days from the Closing Date.

The Company intends to use the net proceeds of the Offering to advance exploration, technical evaluation, and project advancement activities across the Company's mineral asset portfolio, including verification and follow-up work on recently acquired properties, historical data verification, target generation, and early stage field programs, as well as for general working capital and corporate purposes.

Listed Issuer Financing Exemption (LIFE)

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, the Units will be offered for sale to purchasers resident in all of the provinces and territories of Canada, excluding Québec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the "LIFE Exemption"). The Common Shares and Warrant Shares underlying the Units are expected to be immediately freely tradeable under applicable Canadian securities legislation if sold to purchasers resident in Canada.

There will be an offering document (the "Offering Document") related to the Offering that will be accessible under the Company's issuer profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.trinityonemetals.com. Prospective investors should read the Offering Document before making an investment decision.

Closing and Finder's Fees

The Offering is expected to close on or about February 27, 2026, or such other date(s) as may be determined by the Company that is within 45 days from February 10, 2026, and may be completed in one or more tranches. Completion of the Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals, including the conditional approval of the TSX Venture Exchange (the "TSXV"). Finder's fees may be payable in accordance with the policies of the TSXV and applicable securities laws. The Company may pay finder's fees in cash of up to 6.0% of the aggregate gross proceeds of the Offering and may issue non-transferrable warrants equal to 6.0% of the number of Units issued under the Offering to subscribers introduced by finders to the Company.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information is frequently characterised by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and similar words, or statements that certain events or conditions "may" or "will" occur.

Forward-looking information in this news release includes, without limitation, statements relating to: the Offering (including the size of the Offering, the proposed terms of the Units, the expected closing date and ability to complete the Offering); the filing and availability of the Offering Document; the expected use of proceeds; the payment of finder's fees; and the receipt of TSXV and other regulatory approvals.

Forward-looking information is based on certain assumptions and management's expectations and estimates as of the date hereof and is subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the ability of the Company to complete the Offering on the terms described herein or at all; market conditions; the ability to obtain TSXV and other regulatory approvals; changes in the Company's plans with respect to the use of proceeds; and general economic, market and business conditions.

Although the Company believes the expectations reflected in the forward-looking information are reasonable, undue reliance should not be placed on forward-looking information since no assurance can be provided that such expectations will prove to be correct. The Company disclaims any intent or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283371

Source: Trinity One Metals Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us